

# **Japanese Encephalitis (JE)**

## **Vaccine Workgroup**

---

**Joseph A. Bocchini, Jr., M.D.**  
**ACIP, Workgroup Chair**

**February 20, 2013**

# Japanese encephalitis (JE) vaccine in the U.S.

---

- **Inactivated Vero cell culture-derived JE vaccine (JE-VC) is the only JE vaccine licensed and available in the U.S.**
- **JE-VC is approved for use in adults  $\geq 17$  years of age**
- **No JE vaccine is currently licensed and available in the United States for use in children**

# **JE vaccine for children in the U.S.**

---

- **Intercell Biomedical has submitted a BLA for use of JE-VC in children 2 months through 16 years of age**
- **The same indication for use of JE-VC in children was approved by the European Medicines Agency (EMA) earlier this month**

# ACIP JE Vaccine Workgroup activities

---

- **Reactivated the workgroup in October 2012**
- **Met five times thus far to review safety and immunogenicity data for JE-VC in children**
- **Developing recommendations for use of JE-VC in children with expected ACIP vote in June 2013**
- **Today, will present background information on JE risk and current ACIP recommendations for use of JE vaccine for travelers**

# ACIP JE Vaccine Workgroup members

## ACIP

Joseph Bocchini (WG Chair)

Lorry Rubin (ACIP member)

## Ex Officio

Jorge Carrillo (DoD)

Doran Fink (FDA)

Jesse Geibe (DoD)

Lewis Markoff (FDA)

Pat Repik (NIH)

Jeff Roberts (FDA)

## ACIP liaisons

Cody Meissner (AAP)

Robert Schechter (AIM)

Patsy Stinchfield (NAPNAP)

## CDC

Faruque Ahmed (ISD)

Marc Fischer (DVBD)

Mark Gershman (DGMQ)

Susan Hills (DVBD)

Mike McNeil (ISO)

Hardeep Sandhu (GID)

## Technical advisors

Lin Chen

Elizabeth Barnett

Paul Cieslak

David Shlim